Context Therapeutics Files 8-K with Regulatory Disclosures

TL;DR

CTX shares might move on new 8-K filing - check EX-99.1 for details.

AI Summary

On April 2, 2026, Context Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing includes an exhibit, EX-99.1, titled 'a04022026fasttrackdesignat.htm', and various XBRL documents.

Why It Matters

This 8-K filing indicates that Context Therapeutics Inc. is making public disclosures and providing updated financial information, which could be relevant for investors monitoring the company's activities.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant financial distress or major corporate changes.

Key Numbers

• 25511 — iXBRL 8-K Size (Size of the main 8-K document in bytes.)
• 11745 — EX-99.1 Size (Size of the exhibit EX-99.1 in bytes.)

Key Players & Entities

• Context Therapeutics Inc. (company) — Filer of the 8-K report
• 0001842952 (company) — CIK number for Context Therapeutics Inc.
• 2026-04-02 (date) — Filing date of the 8-K report
• EX-99.1 (document) — An exhibit filed with the 8-K

FAQ

Key Financial Figures

• $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check

Filing Documents

• cntx-20260402.htm (8-K) — 25KB
• a04022026fasttrackdesignat.htm (EX-99.1) — 11KB
• image_0.jpg (GRAPHIC) — 194KB
• 0001628280-26-022931.txt ( ) — 431KB
• cntx-20260402.xsd (EX-101.SCH) — 2KB
• cntx-20260402_lab.xml (EX-101.LAB) — 24KB
• cntx-20260402_pre.xml (EX-101.PRE) — 14KB
• cntx-20260402_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On April 2, 2026, Context Therapeutics Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to CTIM-76, the Company's investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

01. Other Events

Item 8.01. Other Events. On April 2, 2026, the Company issued a press release announcing that the FDA has granted Fast Track designation to CTIM-76, the Company's investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Context Therapeutics Inc., dated April 2, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 2, 2026 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR